Myasthenia Gravis Treatment Market By Treatment Type (Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Plasma Exchange & IVIG, Surgical Treatment), By Route of Administration (Oral, Intravenous, Subcutaneous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By End-User (Hospitals, Specialty Clinics, Homecare Settings, Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles, and Market Forecast, 2025 – 2035.

Industry Outlook

The Myasthenia Gravis Treatment market accounted for USD 1.86 Billion in 2024 and is expected to reach USD 4.18 Billion by 2035, growing at a CAGR of around 7.65% between 2025 and 2035. The Myasthenia Gravis Treatment Market serves patients with MG through therapeutics that aim to handle the autoimmune neuromuscular disorder causing persistent muscle weakness. Available treatments help patients reduce symptoms, together with strengthening their muscles and minimizing disease progression. Several kinds of treatments exist within the Myasthenia Gravis market structure, including Cholinesterase Inhibitors alongside Corticosteroids, while Immunosuppressants join them with Monoclonal Antibodies and Plasma Exchange & IVIG and Surgical Treatment.

The treatment methods deliver their medications either by mouth or through IV and subcutaneous routes. The market uses different distribution networks composed of hospital pharmacies as well as retail pharmacies and online pharmacies. The growth of this market will be substantial due to rising disease cases and evolving targeted therapeutic options while patient care receives greater attention and specific treatment development. 

Report Scope:

Market Dynamics

New monoclonal antibodies improve treatment efficacy and patient outcomes.

The Myasthenia Gravis Treatment Market continues to expand because therapeutic monoclonal antibodies have introduced significant therapeutic improvements for managing the condition. The therapeutic agents, including Efgartigimod alfa, work to block and stop the activity of the neonatal Fc receptor (FcRn), thus preventing the recycling of pathogenic immunoglobulin G (IgG) antibodies. The reduction of antibody levels through monoclonal antibodies leads to a decreased autoimmune response, which lessens muscle weakness and fatigue in individuals with MG. Medical evidence demonstrates that Efgartigimod alfa therapy led to daily activity enhancement in 68% of patients, while placebo treatments resulted in only 30% patient improvement.

The recent discovery demonstrates monoclonal antibodies as promising agents for creating better-targeted procedures, which can benefit individuals who do not respond well to conventional medical interventions. The establishment of monoclonal antibodies stands as a fundamental therapeutic approach for MG by satisfying essential patient requirements regarding improved symptom control and enhanced quality of life. Continuous research and development will enable monoclonal antibodies to take a more crucial part in the management of MG, thus generating greater benefits for long-term remission and improved patient outcomes. The Myasthenia Gravis Treatment Market is expected to receive additional growth momentum following the development of focused therapeutic interventions, which can benefit wider patient demographic groups.

Orphan drug designations encourage drug development

Received orphan drug designations strongly motivate pharmaceutical companies to create medical solutions for rare conditions, including Myasthenia Gravis (MG). Drugs qualifying for regulatory agency designations through bodies such as the U.S. Food and Drug Administration (FDA) receive multiple advantages, including tax incentives and exemption from user fees, together with six years of market protection. The market incentive system resulting from these benefits encourages pharmaceutical companies to focus their scientific work on illnesses with small patient populations such as MG.

The U.S. Food and Drug Administration has approved more than 6,300 orphan drugs since 1983, when the agency passed the Orphan Drug Act. In 2021, according to the FDA regulations, more than 1,000 novel treatments were approved for rare diseases, which include MG among them. The support system helps developers create new medical solutions for MG patients by making the process of market treatment development more straightforward. New treatments are emerging in the Myasthenia Gravis Treatment Market due to orphan drug designations, which enhance patient results and grow accessible therapeutic choices.

Monoclonal antibodies and immunosuppressants are expensive.

High expenses associated with monoclonal antibodies along with immunosuppressants limit the market potential of Myasthenia Gravis (MG) treatments. Efgartigimod alfa represents one of several monoclonal antibody products that deliver superior patient results through highly targeted treatment methods. These treatments cost thousands of dollars monthly, so many patients, especially uninsured patients, cannot afford them. Immunosuppressive drugs used for treating autoimmune MG are expensive and necessitate extensive treatment durations.

Medical treatment expenses restrict access to care for numerous patients across the world since they outnumber the resources available in underdeveloped areas. The financial constraints prevent widespread acceptance of advanced and more effective treatment methods, thus reducing market expansion rates. Cost functions as a substantial challenge that affects both patients and healthcare systems when treating MG patients.

Potential for long-term remission and reduced relapses

The Myasthenia Gravis Treatment Market will gain substantial value from developments that create extended symptom-free states and decreased disease relapse occurrences. Improvements in treatment methods that generate sustained remission tend to boost therapy efficiency, thus enhancing the way patients handle Myasthenia Gravis and their daily lives. Extended symptom control and reduced relapse occurrence from treatments lead to improved patient contentment and fuel the market's requirement for novel and powerful therapies.

The market possesses new investment opportunities for pharmaceutical businesses to create long-lasting and efficient therapeutics, thus stimulating growth in this sector. Patients who experience long-term treatment remission show a decreased need for hospital visits and improved drug affordability, thus making medications accessible to more geographical regions. The provision of lasting solutions would generate lasting market demand, thus becoming a fundamental factor for market expansion and creativity.

Remote consultations improve patient access to neurologists.

The Myasthenia Gravis Treatment Market benefits significantly from remote consultation services because it enables more patients to connect with neurologists throughout areas that lack proper healthcare resources. There exists a critical need for both immediate diagnosis and specialized expert handling of MG due to its rarity and medical complexity because this approach results in better treatment success. Specialized neurologists deliver remote consultations to patients from any location so patients avoid time-consuming journeys to access appropriate medical care.

The increased availability of treatment leads to better and more precise medical evaluations and customized therapeutic approaches, and continuous monitoring benefits patients' health outcomes. Telemedicine technology enables healthcare systems to expand their patient network, which subsequently drives up the demand for MG therapeutic options. The growing acceptance of digital healthcare solutions by healthcare providers will lead to enhanced remote consultation practices, which in turn require expanded advanced therapeutic options for better MG management. The market expansion, together with innovation potential, increases substantially through this emerging trend.

Industry Experts Opinion

“Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder that causes weakness in the skeletal muscles. It occurs when the body's immune system mistakenly attacks the communication between nerves and muscles. Although MG can affect anyone, it is most commonly diagnosed in young women and older men. Current treatments, such as acetylcholinesterase inhibitors, immunosuppressants, and thymectomy, are effective in managing symptoms, but the development of novel therapies, including monoclonal antibodies and gene therapy, has significantly improved outcomes. The ongoing research into targeted therapies holds great promise in offering more personalized and effective treatments for patients with MG.”

• Dr. Emily Roberts, Neurologist and Professor at Harvard Medical School

Segment Analysis

Based on the Treatment type, the Myasthenia Gravis Treatment Market has been classified into Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Plasma Exchange & IVIG, and Surgical Treatment. Monoclonal antibodies represent the leading segment of the Myasthenia Gravis Treatment Market because Efgartigimod (Vyvgart) demonstrates high effectiveness in controlling the autoimmune response that causes the disease. The treatment of myasthenia gravis underwent a breakthrough because monoclonal antibodies provide specific medicine that attacks the root cause of the disease instead of relying solely on symptom relief. Patients now prefer monoclonal antibodies because these antibodies effectively decrease symptom intensity and enhance outcome results better than traditional approaches. The market will experience rising dominance from this segment because of precision medicine developments and recent FDA approvals of monoclonal antibodies. The Myasthenia Gravis Treatment Market’s most substantial and leading segment demonstrates growing use due to its effective outcomes.

Based on the Route of Administration, the Myasthenia Gravis Treatment Market has been classified into Oral, Intravenous, and Subcutaneous. The segment of intravenous stands as the dominant choice in the Myasthenia Gravis Treatment Market through its Route of Administration category. Standard medical practice uses this route for delivering plasma exchange and IV immunoglobulin (IVIG) treatments because these therapies yield superior results for myasthenia gravis patients. The fast delivery of medications through intravenous routes directly into the bloodstream enables quick therapeutic effects needed for quickly treating patients who have severe symptoms of myasthenia gravis. The therapeutic value of Efgartigimod, as well as other monoclonal antibodies, depends heavily on intravenous administration. Intravenous delivery of medication at high doses represents a crucial factor that makes this administration route dominate Myasthenia Gravis treatment, specifically in hospital environments.

Regional Analysis

The Myasthenia Gravis Treatment Market in North America advances because of sophisticated medical infrastructure coupled with major disease prevalence rates and significant spending on research activities. The United States occupies the lead position in this market because it maintains strong medical facilities while detecting high numbers of Myasthenia Gravis (MG) patients. The FDA delivers its support to orphan drug designations while enabling innovative treatments such as monoclonal antibodies, which both drive increased market expansion in the region. The growing awareness about the diagnosis has resulted in more people being identified with the condition, thus increasing the need for specialized treatments.

Canada's market segment benefits from universal healthcare funding schemes alongside an emerging effort to enhance patients' treatment access. The market grows through academic and research institutions and government support towards rare disease management, which advances treatment development and better patient results.

The Asia-Pacific Myasthenia Gravis Treatment Market is showing slow growth because patients recognize the disease more, and pharmaceutical treatment choices are becoming more accessible. Three top market leaders in this field are China, India, and Japan because they possess substantial patient numbers and improved healthcare systems. Japan stands among the biggest markets in the region as it maintains strong healthcare systems, and its older population heightens the occurrence of neuromuscular disorders, specifically myasthenia gravis. Innovation within pharmaceutical companies and high research and development activities drive the development of treatment breakthroughs, including monoclonal antibodies.

Competitive Landscape

Several established pharmaceutical companies and emerging entities in the Myasthenia Gravis Treatment Market work to develop innovative medical treatments alongside each other. Efgartigimod (Vyvgart), along with other treatments from Roche and UCB Pharma, constitutes a dominant force in the Myasthenia Gravis Treatment Market since this monoclonal antibody addresses immune system dysfunction to minimize MG symptom intensity. The pharma industry leader, Alexion Pharmaceuticals, produces Soliris (eculizumab) as an immunosuppressive drug that helped establish effective treatment of myasthenia gravis. Mitsubishi Tanabe Pharma joins other major pharmaceutical companies by presenting Raiden as a treatment option for MG symptom management. The immunoglobulin treatment provider, Grifols, offers plasma-derived medical products to the market. The market receives attention from Amgen, Merck, and Novartis as they pursue novel therapy development research. The competitive nature of these companies is driven by research investments and clinical trials as well as regulatory approvals, and it motivates continuous innovation to enhance patient outcomes in MG treatment.

Myasthenia Gravis Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In March 2024, Argenx reported significant growth in its Vyvgart treatment for generalized myasthenia gravis (gMG), with sales more than doubling to $1.19 billion in 2024. This surge was driven by expanded approvals and the introduction of convenient under-the-skin injections. This news highlights the company's strong position in the Myasthenia Gravis Treatment Market..

Report Coverage:

By Treatment Type

• Cholinesterase Inhibitors
• Corticosteroids
• Immunosuppressants
• Monoclonal Antibodies
• Plasma Exchange & IVIG
• Surgical Treatment

By Route of Administration

• Oral
• Intravenous
• Subcutaneous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

End-user

• Hospitals
• Specialty Clinics
• Homecare Settings
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Roche
• Bristol-Myers Squibb
• UCB Pharma
• Alexion Pharmaceuticals
• Mitsubishi Tanabe Pharma
• Sanofi
• Grifols
• Amgen
• Eisai Co. Ltd.
• Merck & Co., Inc.
• Novartis
• GSK (GlaxoSmithKline)
• AbbVie
• Teva Pharmaceutical Industries Ltd.
• Sandoz

Frequently Asked Questions (FAQs)